Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies

Inclusion Criteria for All Participants: * Age 40-75 years at the day of consenting to the study. * Able to provide a written informed consent. Additional Inclusion Criteria for Cancer Participants: * No prior cancer treatment (local or systematic) prior to blood draw. * High suspicious or pathologically confirmed lymphoid malignancies within 42 days prior to blood draw. Additional Inclusion Criteria for Benign Disease Participants: * No prior radical treatment of the benign diseases prior to study blood draw * Pathologically confirmed diagnosis of lymphoid benign diseases within 90 days prior to blood draw. Exclusion Criteria for All Participants: * Insufficient qualified blood samples. * During pregnancy or lactation. * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * Recipient of blood transfusion within 7 days prior to blood draw. * Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen). Additional Exclusion Criteria for Cancer Participants: * With other known malignant tumors or multiple primary tumors. * Lymphoid malignancies unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw. Additional Exclusion Criteria for Benign Disease Participants: * With other known malignant tumors or comfirmed lymphoid malignancies. * Lymphoid benign diseases unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.